Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

<p>Treemap of most common drug mechanisms for patients treated in biomarker-matched studies.</p>

Enregistré dans:

Détails bibliographiques
Auteur principal:	Roberto Carmagnani Pestana (15294422) (author)
Autres auteurs:	Justin T. Moyers (15047706) (author), Jason Roszik (15017091) (author), Shiraj Sen (15294425) (author), David S. Hong (15019257) (author), Aung Naing (15023555) (author), Cynthia E. Herzog (15012524) (author), Siqing Fu (15047712) (author), Sarina A. Piha-Paul (15294428) (author), Jordi Rodon (15047721) (author), Timothy A. Yap (15028749) (author), Daniel D. Karp (15294431) (author), Apostolia M. Tsimberidou (15294434) (author), Shubham Pant (15122815) (author), Maria A. Zarzour (15294437) (author), Ravin Ratan (15044195) (author), Vinod Ravi (15047730) (author), Robert S. Benjamin (15012521) (author), Alexander J. Lazar (14963562) (author), Wei-Lien Wang (15294440) (author), Najat Daw (15294443) (author), Jonathan B. Gill (15086581) (author), Douglas J. Harrison (15294446) (author), Valerae O. Lewis (15294449) (author), Christina L. Roland (15294452) (author), Shreyaskumar R. Patel (15062448) (author), J. Andrew Livingston (15294455) (author), Neeta Somaiah (14963553) (author), Joseph A. Ludwig (15016911) (author), Anthony P. Conley (15294458) (author), Nelson Hamerschlak (15294461) (author), Richard Gorlick (15019631) (author), Funda Meric-Bernstam (10258780) (author), Vivek Subbiah (8737068) (author)
Publié:	2025
Sujets:	Cancer Therapeutic Research and Development Clinical Research and Trials Biological Agents & Therapies Drug Targets Precision Medicine Sarcomas
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

SPIRIT schedule of enrollment, interventions, and assessment.
par: Kim Christin Honselmann (21176936)
Publié: (2025)

Participant timeline: Schedule of enrollment, interventions, and assessments.
par: Pierre Angelvy (22683450)
Publié: (2025)

A table showing the clinical participants who were enrolled in a further or higher education course and their research activity and self-declared involvement.
par: Zoe Edwards (3823528)
Publié: (2025)

Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
par: James S. Wilmott (15008931)
Publié: (2025)

Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
par: James S. Wilmott (15008931)
Publié: (2025)

Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
par: Iris van 't Erve (15054503)
Publié: (2025)

Serum neuregulin -1 (NRG-1) is a potential biomarker for early diagnosis and prediction in refractory schizophrenia
par: Ming Shu (22683656)
Publié: (2025)

Figure 1 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
par: Marianna Carrabotta (8193039)
Publié: (2025)

Figure 2 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
par: Marianna Carrabotta (8193039)
Publié: (2025)

Figure 3 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
par: Marianna Carrabotta (8193039)
Publié: (2025)

Figure 4 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
par: Marianna Carrabotta (8193039)
Publié: (2025)

Figure 5 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
par: Marianna Carrabotta (8193039)
Publié: (2025)

Table 1 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
par: Marianna Carrabotta (8193039)
Publié: (2025)

Figure S1 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
par: Sebastian Johannes Schober (14971891)
Publié: (2025)

Figure S2 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
par: Sebastian Johannes Schober (14971891)
Publié: (2025)

Figure S3 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
par: Sebastian Johannes Schober (14971891)
Publié: (2025)

Figure S4 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
par: Sebastian Johannes Schober (14971891)
Publié: (2025)

Figure S5 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
par: Sebastian Johannes Schober (14971891)
Publié: (2025)

Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
par: Milana A. Bergamino (15038015)
Publié: (2025)

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
par: Milana A. Bergamino (15038015)
Publié: (2025)

Figure 3 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
par: Milana A. Bergamino (15038015)
Publié: (2025)

Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
par: Milana A. Bergamino (15038015)
Publié: (2025)

Figure 5 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
par: Milana A. Bergamino (15038015)
Publié: (2025)

Figure 6 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
par: Milana A. Bergamino (15038015)
Publié: (2025)

Supplementary Table 1 from Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase–mutant Astrocytic and Oligodendroglial Tumors
par: David Olayinka Kamson (16617218)
Publié: (2025)

Supplementary Table 2 from Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase–mutant Astrocytic and Oligodendroglial Tumors
par: David Olayinka Kamson (16617218)
Publié: (2025)

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
par: Nigel Bundred (15046233)
Publié: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
par: Nigel Bundred (15046233)
Publié: (2025)

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
par: Nigel Bundred (15046233)
Publié: (2025)

Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
par: Nigel Bundred (15046233)
Publié: (2025)

Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
par: Nigel Bundred (15046233)
Publié: (2025)

Table S1. Isometric handgrip force-matched participant demographics and LV morphology.
par: Corey Tomczak (22648301)
Publié: (2025)

Data_Sheet_1_Benchmarking quantum annealing with maximum cardinality matching problems.PDF
par: Daniel Vert (18769933)
Publié: (2025)

<b>Figure S1.</b><b> Cardiac MRI LV volume responses to EX and MMA in</b><b> </b><b>i</b><b>sometric handgrip force-matched-matched males and females</b>
par: Corey Tomczak (22648301)
Publié: (2025)

Supplementary Figure S1 from A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes
par: Benjamin K. Wilke (15055112)
Publié: (2025)

Supplementary Figure S2 from A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes
par: Benjamin K. Wilke (15055112)
Publié: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
par: Tom Wei-Wu Chen (15053003)
Publié: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
par: Tom Wei-Wu Chen (15053003)
Publié: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
par: Tom Wei-Wu Chen (15053003)
Publié: (2025)

Supplementary Figure 4 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
par: Tom Wei-Wu Chen (15053003)
Publié: (2025)

Cannot write session to /tmp/vufind_sessions/sess_rbb6c619n4g885kji5hig9bujg